A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
The PIEDA Study: A Phase 3b Investigation of Erythropoietin Drugs Using A Specified Dosing Algorithm: A Randomized Open Label Dosing Study in Adult Chronic Kidney Disease Subjects on Hemodialysis
Category & Conditions: Cardiovasular Diseases and Conditions
Medicine: RETACRIT INJECTION(EPOETIN ALFA-EPBX)
ClinicalTrials.gov Identifier (NCT): NCT02504294
Protocol ID: C3461008
PrintDownloadOpen Plain Language Summary Result: Click here